Case and control samples were collected from the St. Antonius Hospital ILD biobank, screening all sarcoidosis patients (n = 2265) for eligibility. Cases were selected based on pulmonary treatment indication (decrease in lung function, dyspnea or pulmonary fibrogenesis), treatment with prednisone or MTX, and presence of serum collected within 6 months prior to start of treatment. 98 sarcoidosis patients were treated with MTX and 69 patients treated with prednisone.
